Quality of 2 nd line medicines for tuberculosis. Ms Lisa Hedman World Health Organization Department of Essential Medicines and Health Products
|
|
- Margery McBride
- 5 years ago
- Views:
Transcription
1 Quality of 2 nd line medicines for tuberculosis Ms Lisa Hedman World Health Organization Department of Essential Medicines and Health Products
2 Case studies in medicines for tuberculosis Outline: Statistics overview Quality standards: case studies of problems Access to quality medicines Challenges in generating clear demand for quality products
3 WHO REPORT 2011 GLOBAL TUBERCULOSIS CONTROL
4 Characteristics of market 650,000 of 9 million annual cases are predicted to need second line treatment will be children. Highest burden countries are low- and middle-income Manufacturing by international generics and local producers in highest burden countries Dx capacity is limited, inhibits demand for treatment Paediatric products are essentially unavailable
5 WHO Prequalified 2 nd line medicines Prequalification available: PQ suppliers Other SRA suppliers Amikacin, solution injection 500 mg/2 ml vial, amp; powder for injection 1g vial, amp Capreomycin, powder for injection 1g, vial Cycloserine, capsule 250 mg Ethionamide, tablet /capsule 250 mg Kanamycin, powder for injection 1g, vial Kanamycin, powder for injection 500 mg, vial Levofloxacin, tablet /capsule 250 mg, tablet 500 mg, tablet 750 mg Moxifloxacin, tablet /capsule 400 mg Ofloxacin, tablet /capsule 200 mg; 400 mg Prothionamide, tablet /capsule 250 mg Para-Aminosalicylic Acid (PAS) sachets, 4 g granules PAS Sodium 100 g jar granules, 4g / 9.2 g sachets granules; powder for oral Other SRA suppliers include sources identified in the US, Europe and Canada. Numbers are approximate and do not count potentially redudant sources. Total
6 Study of PQ and non PQ medicines Non-compliant Compliant 100% 80% 60% % 20% % Isoniazid tabl Isoniazid inj Rifampicin caps Kanamycin powder Isoniazid/Rifampicin tabl Ofloxacin tabl Ofloxacin caps Ofloxacin inf
7 No sample suspected to be of spurious, falsely-labelled, falsified or counterfeit product Failure rate Total = 11.3% 10.3% 1.0% 88.7% Compliant Nonextreme deviations Extreme deviations Extreme deviation arbitrarily defined as the content of API deviating by more than 20% from the declared content and/or average dissolution of tested units lower than 25% below pharmacopoeia Q value
8 Other cases studies Pakistan, May 2012: Toxic level of anti-malarial API replaced a standard excipient Over 120 deaths and 400 SAEs Green Light studies Patient outcome information was inconclusive Facilities reported mix of medicine sources and outcomes Literature searches did not yield studies on clinical outcomes Pharmacovigilance reporting not conclusive
9 Pharmacovigilance in TB medicines Country TB cases, 2010 report India 1,500,000 China 900,000 South Africa 400,000 Pakistan 270,000 Indonesia 239,871 Brazil 194,946 Bangladesh 160,000 Russian Federation 142,958 Philippines 93,261 Vietnam 87,848 3,988,884 x length of treatment x number of meds per patient Total pharmacovigilance needs
10 NEED ACCESS Other factors EML 2013 WHO PQ SRA Donors Pricing Policy Regulatory Financing Manufacturing Supply Demand (provider) Monitoring Stock outs
11 Policy and Prequalification Global policies and invitations for PQ are available but response and uptake to both are low.
12 Small market burdens of influence Example Countries Price controls Low price rules Mixed funders Exporter Production capacity China? WHO policies? India South Africa Financial influences availability Local policy
13 WHO REPORT 2011 GLOBAL TUBERCULOSIS CONTROL Some signals for national funding
14 Weak supply chain monitoring Consumption data? Prescription studies? Wastage figures? Where are the real data from countries?
15 Conclusion High risk environment Insufficient data to support "risk based" approach to quality assurance Available data show real problems
THE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION
1 THE NEW DR-TB NATIONAL POLICY AND STATE OF IMPLEMENTATION Dr. Norbert Ndjeka MD, DHSM (Wits), MMed(Fam Med) (MED), Dip HIV Man (SA) Director Drug-Resistant TB, TB and HIV National Department of Health
More informationSummary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing - PRELIMINARY -
Summary of outcomes from WHO Expert Group Meeting on Drug Susceptibility Testing PRELIMINARY 4 th Annual GLI meeting 17 April 2012 Fuad Mirzayev Laboratories, Diagnostics and Drug Resistance unit, Stop
More informationChallenges to treat MDR TB
Challenges to treat MDR TB Manfred Danilovits Tartu University Hospital, Estonian NTP Program 2nd European Advanced Course in Clinical Tuberculosis 22-24 September 2014, Amsterdam MDR-TB control; WHO Europe,
More informationDrug-resistant TB therapy: the future is now
Drug-resistant TB therapy: the future is now Gary Maartens Thanks to Francesca Conradie for sharing slides Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN
More informationWHO Global Surveillance and Monitoring System SSFFC Medical Products (Substandard, Spurious, Falsely labelled, Falsified and Counterfeit)
WHO Global Surveillance and Monitoring System SSFFC Medical Products (Substandard, Spurious, Falsely labelled, Falsified and Counterfeit) TECHNICAL BRIEFING SEMINAR 2016 What does SSFFC mean? Counterfeit
More information- the details, where possible, of the antibiotic products these companies supply or have supplied.
Under the Freedom of Information Act 2000 please could you provide me with a list of all companies currently supplying antibiotics - or that have supplied antibiotics in the last three years - to Royal
More informationClinical Management : DR-TB
Clinical Management : DR-TB Charoen Chuchottaworn MD., Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH. Tuberculosis Classification Drug susceptible TB
More informationQuality of veterinary medicines
Quality of veterinary medicines Regional Seminar for OIE National Focal Points for Veterinary Products Tokyo, 2 March 2016 Dr. Yoshihiro Shimizu, DVM Executive Director, Asian Animal Health Association
More informationMulti-Drug and Extensively Drug Resistant Tuberculosis
Multi-Drug and Extensively Drug Resistant Tuberculosis Gwen A. Huitt, M.D., M.S. Professor, Department of Medicine Director, Adult Infectious Disease Care Unit National Jewish Health Disclosures None Tuberculosis
More informationDR-TB PATIENT IDENTITY CARD
Ministry of Health Community Development Gender Elderly and Children National Tuberculosis and Leprosy Programme DR-TB 02 DR-TB Treatment Unit: DR-TB PATIENT IDENTITY CARD DR-TB Reg. Number: Date of registration:
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 29 October 2014 GRANUPAS, gastro-resistant granules 30 sachets with a calibrated measuring spoon (CIP: 34009 278 801
More informationManagement of MDR and XDR TB Prof. Martin Boeree
Management of MDR and XDR TB 1, MD, PhD Associate Professor Consultant Respiratory Medicine Department of Lung Diseases Radboud University Nijmegen Medical Centre TB Referral Hospital Dekkerswald Nijmegen,
More informationMDR-TB drugs per WHO guidelines
New antituberculous agents for drug-resistant resistant TB Symposium Belgian Society of Infectiology and Clinical Microbiology November 9 Jens Van Roey, MD - Tibotec Definitions MDR-TB multidrug resistance
More informationRate In Rs.Ps (ED Included. Tax Extra) Sl No Name Of The Product Pack. Scheduled And Non-Scheduled Formulations Capsules
KAPL list of products applicable for Institutional/Hospital supplies under Pharmaceuticals Purchase Policy (PPP) issued by Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Govt. of India
More informationTB Intensive Houston, Texas. Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD
TB Intensive Houston, Texas November 10-12, 12 2009 Multi-Drug Resistant (MDR) TB Barbara Seaworth, MD November 12, 2009 Multi-Drug Resistant (MDR) TB Updates November 12, 2009 Barbara J. Seaworth Professor
More informationMDR treatment. Shanghai, May 2012 Arnaud Trébucq The Union
MDR treatment Shanghai, May 2012 Arnaud Trébucq The Union Why to diagnose MDR-TB? Outcome of SS+ new MDR-TB cases, treated with First Line TB (FLD) drugs Setting Success Died Fail LFFU Transf. Corea 20(56)
More informationI am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Antibiotics.
Ref: FOI/CAD/ID 3459 27 June 2017 Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone Kent ME16 9QQ Email: mtw-tr.foiadmin@nhs.net Freedom of Information Act
More informationEffects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB)
Effects of Moxifloxacin PK-PD and drug interactions on its use in the Treatment of Tuberculosis(TB) Session: Fanning the Flames of HIV and TB Cointeraction SA AIDS Conference-Durban ICC 13-15 June 2017
More informationSession 1: An introduction to the new requirements under the Food and Drug Regulations affecting industry and health care practitioners who compound
Session 1: An introduction to the new requirements under the Food and Drug Regulations affecting industry and health care practitioners who compound veterinary drugs February 13, 2018 Webinar Presentation
More informationMoxifloxacin (as hydrochloride) 400 mg Tablets WHOPAR part 6 November 2017 (Hetero Labs Limited), TB 315
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationDr Dean Shuey Team Leader Health Services Development WPRO. World Health Day Antimicrobial Resistance: The Global and Regional Situation
Dr Dean Shuey Team Leader Health Services Development WPRO World Health Day 2011 Antimicrobial Resistance: The Global and Regional Situation 2 7 April 2011 World Health Day No action today, no cure tomorrow
More informationIllegal veterinary medicines
Illegal veterinary medicines Regional Seminar for OIE National Focal Points for Veterinary Products Beirut, Lebanon, 7-9 November 2017 Philippe Sabot on behalf of HealthforAnimals. www.animalhealthmatters.org
More informationMDR/XDR TB. Barbara Seaworth, MD, FIDSA, FACP October 27, TB Intensive October 24 27, 2017 San Antonio, TX
MDR/XDR TB Barbara Seaworth, MD, FIDSA, FACP October 27, 2017 TB Intensive October 24 27, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Barbara Seaworth, MD, FIDSA, FACP, has the following disclosures
More informationTreatment of Multidrug-resistant Tuberculosis (MDR-TB)
Treatment of Multidrug-resistant Tuberculosis (MDR-TB) 2006 2008 2011 2013 2014 2016 2019 Charles L. Daley, MD National Jewish Health University of Colorado Disclosures Research grant Insmed: Phase II
More informationMultidrug-resistant Tuberculosis. Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership
Multidrug-resistant Tuberculosis Charles L. Daley, MD National Jewish Health Chair, Global GLC, WHO and Stop TB Partnership Disclosures World Health Organization Chair, Global GLC Otsuka Chair, Data Monitoring
More informationDrug resistant TB: The role of the laboratory
Drug resistant TB: The role of the laboratory 26 Oct 2012 Andrew Whitelaw NHSLS / UCT TB lab functions: Outline Resistance testing Genotypic Phenotypic Which tests are done when, and why Reporting of
More informationExploring Novel Approaches to Shared TB Laboratory Services: California-Wisconsin Shared Services Pilot Study
Exploring Novel Approaches to Shared TB Laboratory Services: California-Wisconsin Shared Services Pilot Study Julie Tans-Kersten, MS, BS-MT (ASCP) Tuberculosis Laboratory Program Coordinator Wisconsin
More informationQuality of veterinary medicines
Quality of veterinary medicines Regional Seminar for OIE National Focal Points for Veterinary Products Entebbe, Uganda, 1-3 December 2015 Olivier Espeisse (Elanco), speaking on behalf of HealthforAnimals
More information3 party manufacturing PRODUCT LIST. Category : ANTI BIOTIC
rd 3 party manufacturing PRODUCT LIST Category : ANTI BIOTIC ANTI BIOTIC SR.NO. COMPOSTION DRUG/FOOD DOSAGE PACKING 1 Amikacin Sulphate IP 500mg/2ml DRUG LIQUID INJ. VIAL 2 Amoxicillin 200mg & Clavulanic
More informationNew drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick
New drugs and regimens for treatment of drug-sensitive TB (DS-TB) Patrick Phillips Patrick.Phillips@ucsf.edu @PPJPhillips Outline Overview of regimen development strategies 1-3 year horizon: Ongoing phase
More informationStrategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S.
Strategies for Successful Treatment of Drug Resistant Tuberculosis in the U.S. Barbara J. Seaworth, M.D. Professor of Medicine University of Texas Health Science Center, Tyler Medical Director, Heartland
More informationTB Grand Rounds. MDR-TB: Management of Adverse Drug Reactions. Reynard J. McDonald, M.D. September 18, Patient History
TB Grand Rounds MDR-TB: Management of Adverse Drug Reactions Reynard J. McDonald, M.D. September 18, 2007 Patient History This 30 y/o H/M was born in Ecuador and immigrated to the US in 2001 On 11-22-05
More informationSCHEDULE P LIFE PERIOD OF DRUGS. [See rule 96] Conditions of storage
SCHEDULE P [See rule 96] LIFE PERIOD OF DRUGS No. Name of the Drug Period in months (unless otherwise specified) between date of manufacture and the date of expiry which the labelled potency period of
More informationGlobal Monthly October 2016
Jan- Feb- Mar- Apr- May- Jun- Jul- Aug- Sep- Global Monthly Index, >5 = expansion 5 Output Export orders 5 9 http://www.worldbank.org/en/research/brief/economic-monitoring Sept ' Dec '5 Sept ' Sept ' Dec
More informationTreatment of MDR/XDR-TB. Short course chemotherapy for MDR-TB: practical issues. CHIANG Chen-Yuan MD, MPH, DrPhilos
Treatment of MDR/XDR-TB Short course chemotherapy for MDR-TB: practical issues CHIANG Chen-Yuan MD, MPH, DrPhilos Treatment strategies for MDR-TB Standardized treatment: drug resistance survey data from
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 Drug Resistant TB Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received research funding from
More informationFAO contributing to the AMR Global and Regional Action Plans. Peter Black Deputy Regional Manager FAO RAP ECTAD
FAO contributing to the AMR Global and Regional Action Plans Peter Black Deputy Regional Manager FAO RAP ECTAD FAO contributing to the AMR Global Action Plan AMR is not a stand-alone issue. 68 th World
More informationScientific Discussion post-authorisation update for Rheumocam extension X/007
5 May 2011 EMA/170257/2011 Veterinary Medicines and Product Data Management Scientific Discussion post-authorisation update for Rheumocam extension X/007 Scope of extension: addition of 20 mg/ml solution
More informationLinezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India
Eur Respir J 2012; 39: 956 962 DOI: 10.1183/09031936.00076811 CopyrightßERS 2012 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India R.
More informationACC&D 5 th International Symposium on Non-Surgical Contraceptive Methods of Pet Population Control
Could your organization use calcium chloride? Nuts and Bolts Getting involved in field testing of nonsurgical sterilants: Lessons learned, and what organizations and veterinarians should consider when
More informationPublic Assessment Report. Scientific discussion. Xiflodrop 5 mg/ml eye drops, solution. Moxifloxacin hydrochloride DK/H/2221/001/DC
Public Assessment Report Scientific discussion Xiflodrop 5 mg/ml eye drops, solution Moxifloxacin hydrochloride DK/H/2221/001/DC This module reflects the scientific discussion for the approval of Xiflodrop.
More informationDrug Resistant Tuberculosis:
Drug Resistant Tuberculosis: Pearls and other Considerations John W. Wilson, MD Associate Professor of Medicine Division of Infectious Diseases Mayo Clinic, Rochester MN Mayo Clinic Center for Tuberculosis
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More informationTreatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France
Treatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France First step = To diagnose NTM disease One NTM positive sample NTM disease
More informationTreatment of Drug Resistant TB
Treatment of Drug Resistant TB Diana M. Nilsen RN, MD Bureau of TB Control New York City Department of Health & Mental Hygiene Objectives Definition of other drug resistant (ODR), multiple drug resistant
More informationAntimicrobial resistance: the challenges for animal health
Elisabeth Erlacher Vindel Deputy Head of the Scientific and Technical Departement World Organisation for Animal Health (OIE) Antimicrobial resistance: the challenges for animal health Rabat, 17 Feb. 2015
More informationMultidrug resistant tuberculosis. Where next? Professor Peter D O Davies (Liverpool)
Multidrug resistant tuberculosis. Where next? Professor Peter D O Davies (Liverpool) DOTS + and LTBI New drugs for TB and the challenge of resistance talk plan 1. Epidemiology 2. Treatment 3. The MDRTB
More informationIn Vitro Activities of Linezolid against Clinical Isolates of ACCEPTED
AAC Accepts, published online ahead of print on April 00 Antimicrob. Agents Chemother. doi:./aac.001-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationAMOXICILLIN AND CLAVULANIC ACID TABLETS Draft proposal for The International Pharmacopoeia (February 2018)
February 2018 Draft for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 AMOXICILLIN AND CLAVULANIC ACID TABLETS Draft
More informationHow action in India can have global impact: The Indian pharmaceutical industry and antimicrobial resistance
BRIEFING PAPER How action in India can have global impact: The Indian pharmaceutical industry and antimicrobial resistance 12 February 2018 By Jayasree K. Iyer, Anna Massey, Karrar Karrar and Adrián Ruiz,
More informationTuberculosis in 2017: Searching for new solutions in the face of new challenges
Tuberculosis in 2017: Searching for new solutions in the face of new challenges 6th TB Symposium Ministry of Health of the Republic of Belarus, Republican Scientific and Practical Center for Pulmonology
More informationUniversité catholique de Louvain, Louvain Drug Research Institute, Brussels, Belgium. Bayer Santé SAS, Loos, France
Communicating Comprehensive Safety Data Gained from Clinical Trials to the Scientific Community: Opportunities and Difficulties from an Example with Moxifloxacin P.M. Tulkens, 1 P. Arvis, 2 F. Kruesmann,
More informationJaipur Declaration on Antimicrobial Resistance
Jaipur Declaration on Antimicrobial Resistance We, the Health Ministers of Member States of the WHO South-East Asia Region participating in the Twenty-ninth Health Ministers Meeting in Jaipur, India, appreciate
More informationRegistered Drug Product List:
354 Aguirre Ave. Phase III BF Homes Parañaque City, Metro Manila Philippines +63 2 829 7294/ 826 4902 +63 2 820 4151 Email: info@saharint.com / private_2ii@hotmail.com Antibiotic Line Products: 1 P age
More informationEpidemiology and Economics of Antibiotic Resistance
Epidemiology and Economics of Antibiotic Resistance Eili Y. Klein February 17, 2016 Health Watch USA Meeting I. The burden of antibiotic resistance is a growing global threat, but hard numbers are lacking
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 MDR/XDR TB Barbara J. Seaworth, MD October 16, 2013 Barbara J. Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial
More informationChina Chemical & Pharmaceutical Co., Ltd. Introduction of Animal Health Division
China Chemical & Pharmaceutical Co., Ltd. Introduction of Animal Health Division Outline Overview of CCPC and Affiliates Vision & Core Value Plants Sites Organization Animal Health Division Review Tainan
More informationEXPERIENCE ON ANTIMICROBIAL USE AND RESISTANCE IN KENYA
EXPERIENCE ON ANTIMICROBIAL USE AND RESISTANCE IN KENYA PRESENTED BY DR. NATHAN K. SONGOK National Focal Point Veterinary Medicinal Products Kenya At the Regional Seminar for OIE National Focal Points
More informationMDR TB AND CASE STUDIES
MDR TB AND CASE STUDIES Chris Keh, MD Director, TB Prevention and Control Program, SFDPH HS Assistant Clinical Professor, Infectious Diseases, UCSF Seattle, CITC Clinical Intensive June 15, 2018 Slide
More informationKAZAGRO. National Management Holding. Analytical review of poultry meat market
KAZAGRO National Management Holding Analytical review of poultry meat market 1 Content pages INTRODUCTION 3 1. FOREIGN MARKET 4 1.1 World market of poultry meat 4 1.2 World consumption of poultry meat
More informationOIE global strategy for rabies control, including regional vaccine banks
Inception meeting of the OIE/JTF Project for Controlling Zoonoses in Asia under the One Health Concept OIE global strategy for rabies control, including regional vaccine banks Tokyo, Japan 19-20 December
More informationCDC s Molecular Detection of Drug Resistance (MDDR) Service and Mycobacterium tuberculosis DST Model Performance Evaluation Program (MPEP)
CDC s Molecular Detection of Drug Resistance (MDDR) Service and Mycobacterium tuberculosis DST Model Performance Evaluation Program (MPEP) Beverly Metchock, DrPH, D(ABMM) Mycobacteriology Laboratory Branch/Division
More informationDr Sharanjit Dhoot. Chelsea and Westminster Hospital, London. 18 th Annual Conference of the British HIV Association (BHIVA)
18 th Annual Conference of the British HIV Association (BHIVA) Dr Sharanjit Dhoot Chelsea and Westminster Hospital, London 18-20 April 2012, The International Convention Centre, Birmingham 18 th Annual
More informationGetachew Jember. Country Presentation: Activities carried out so far in regulation of veterinary products, Ethiopia
Country Presentation: Activities carried out so far in regulation of veterinary products, Ethiopia Getachew Jember Regional Seminar for OIE National Focal Points for Veterinary Products 5 th Cycle Ezulwini,
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas May 6 9, 2014 MDR/XDR TB Barbara Seaworth, MD May 9, 2014 Barbara Seaworth, MD has the following disclosures to make: No conflict of interests No relevant financial relationships
More informationSupport for OIE Member Countries OIE PVS / Gap Analysis, Reference Laboratories and twinning programmes
OIE Focal Point Seminar on Veterinary Products Vienna, Austria, November 20-22 2012 Support for OIE Member Countries OIE PVS / Gap Analysis, Reference Laboratories and twinning programmes N. Leboucq OIE
More informationRegional Workshop for VEEs and VSBs
Regional Workshop for VEEs and VSBs Incheon, R.O. Korea, 31 Aug.-01 Sep. 2017 World Organisation for Animal Health Protecting animals, Preserving our future 1 Regional Workshop for VEEs and VSBs Incheon,
More informationGood governance and the evaluation of Veterinary Services
Regional Seminar for OIE National Focal Points for Veterinary Laboratories 5-7 April 2016, Jeju, Republic of Korea Good governance and the evaluation of Veterinary Services Dr. Pennapa Matayompong OIE
More informationRegional Analysis of the OIE PVS Missions in South-East Asia with a focus on APFS
Regional Analysis of the OIE PVS Missions in South-East Asia with a focus on APFS Regional Seminar for OIE National Focal Points for Animal Production Food Safety Hanoi, Vietnam, 24-26 June 2014 Dr Agnes
More informationInterventions: Disease Prevention and Antimicrobial Use Reduction - Overview
Global Antibiotic Resistance Partnership South Africa Inaugural meeting. Stellenbosch, South Africa 8-9 Feb, 2010 Interventions: Disease Prevention and Antimicrobial Use Reduction - Overview Iruka N Okeke
More informationQUALITY HEALTH CARE YOUR PREFERRED PARTNER IN. For better health
YOUR PREFERRED PARTNER IN QUALITY HEALTH CARE For better health Manufacturer of Pharmaceutical Products Eka Pharma 308, Samanvay Zillion, Gotri - Sevasi Road, Opp. Shaishav School, Vadodara-391 101, (Guj.)
More informationISMP Canada HYDROmorphone Knowledge Assessment Survey
ISMP Canada HYDROmorphone Knowledge Assessment Survey Knowledge Assessment Questions 1. In an equipotent dose, HYDROmorphone is more potent than morphine. True False Unsure 2. HYDROmorphone can be given
More informationPerspective on AnA Global timicrobial Resistance
National Center for Emerging and Zoonotic Infectious Diseases Perspective on AnA Global timicrobial Resistance Dawn M. Sievert, PhD, MS Associate Director for Antimicrobial Resistance Division of Foodborne,
More informationDrug Utilization and Evaluation of Restricted Anti-Microbials at CWM Hospital
Drug Utilization and Evaluation of Restricted Anti-Microbials at CWM Hospital BY PHARMACY INTERNS 2007: ANNA ROSE PAVIHI MAKELESI COLATI VEEBHA CHAUHAN ANSHIL CHAND RAIJELI KAUYACA NAMRATA SINGH INTRODUCTION
More informationRisk Factors for Poor Outcomes in Patients with Multi-Drug Resistant Tuberculosis in South Korea
Hanyang Med Rev 2016;36:262-268 https://doi.org/10.7599/hmr.2016.36.4.262 pissn 1738-429X eissn 2234-4446 Original Article Risk Factors for Poor Outcomes in Patients with Multi-Drug Resistant Tuberculosis
More informationGAPFA PET FOOD SAFETY GUIDANCE. PFAC, Niagara-on-the-Lake 2 November 2017
GAPFA PET FOOD SAFETY GUIDANCE PFAC, Niagara-on-the-Lake 2 November 2017 Global Alliance of Pet Food Associations (GAPFA) - Members Pet Food Industry Association of Australia Associação Nacional dos Fabricantes
More informationThe role of FAO in AMR
The role of FAO in AMR Dr. Friederike Mayen, DVM, MSc, PhD FAO Senior Livestock Development Officer FAO Regional Office for the Near East and North Africa (RNE), Cairo, Egypt Why Antimicrobials in Livestock?
More informationMonitoring gonococcal antimicrobial susceptibility
Monitoring gonococcal antimicrobial susceptibility The rapidly changing antimicrobial susceptibility of Neisseria gonorrhoeae has created an important public health problem. Because of widespread resistance
More informationCreating a global community for clinical drug repurposing and development. Leonard Sacks Center for drug evaluation and research FDA
Creating a global community for clinical drug repurposing and development Leonard Sacks Center for drug evaluation and research FDA Neglected tropical diseases 1) Repurposing and developing new drugs 2)
More informationPrivate Sector Perspectives IFAH (worldwide)
OIE National Focal Points for Veterinary Products training Johannesburg, SouthAfrica, 23 26 November2010 Private Sector Perspectives IFAH (worldwide) Barbara Freischem IFAH, Executive Director Presentation
More informationOmeprazole Capsule TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics
Omeprazole Capsule, Omeprazole Capsule India, Omeprazole Capsule manufacturers India, side effects Omeprazole Capsule manufacturers, Taj Pharma India, Omeprazole Capsule overdose, Omeprazole Capsule drug,
More informationCombating Antimicrobial Resistance: A Manufacturing Perspective
Combating Antimicrobial Resistance: A Manufacturing Perspective Steve Brooks VP, EHS Pfizer Inc & Chair, Environmental Work Group of the AMR Industry Alliance June 20 th 2017 AMR - Environmental Matters
More informationAmerican Veterinary Medical Association
AVMA American Veterinary Medical Association Governmental Relations Division 1910 Sunderland Place, NW Washington, DC 20036-1642 phone 202.789.0007 800.321.1473 fax 202.842.4360 AVMA Headquarters 1931
More informationMultidrug resistant Tuberculosis
Multidrug resistant Tuberculosis Pennan Barry, MD, MPH California MDR TB Consult Service Surveillance and Epidemiology Section Curry International Tuberculosis Center Clinical Intensive October 018 Objectives
More informationMultidrug-resistant Tuberculosis
Multidrug-resistant Tuberculosis Pennan Barry, MD, MPH California MDR TB Consult Service Surveillance and Epidemiology Section Curry International Tuberculosis Center Clinical Intensive September 2016
More informationPRODUCT-LIST KENVISH HEALTHCARE
PRODUCT-LIST TABLETS SR. PRODUCT COMPOSITION PACK PKING 1 Exopan-40 PANTAPRAZOLE 40 MG 2 Exopan-D PANTAPRAZOLE 40 MG+DOMPERIDONE 10 MG 3 Kenvizole-20 RABEPRAZOLE 20 MG 4 Kenvizole-D RABEPRAZOLE 20 MG+DOMPERIDONE
More informationASSESSMENT OF COMMONLY AVAILABLE ANTIMICROBIAL AGENTS. A STUDY FROM ILALA-TANZANIA.
ASSESSMENT OF COMMONLY AVAILABLE ANTIMICROBIAL AGENTS. A STUDY FROM ILALA-TANZANIA. By: Malaika Paul (B.PHARM4, MUHAS-2008/2009) ABSTRACT Objective Microbiological assessment of commonly available antimicrobial
More informationEvaluation of Performance of Veterinary Services - Viet Nam experience
Evaluation of Performance of Veterinary Services - Viet Nam experience 3 rd Coordination Conference for ZDAP Da Nang, Viet Nam, 28-30 August 2018 Dr Do Huu Dung Head, Planning Division Department of Animal
More information+91-8071676073 Grapple Life Sciences Private Limited http://www.grapplelifesciences.com/ Our organization is engaged in the supplying, wholesaling, trading and service providing of Pharmaceutical Medicine.
More informationMDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2
1 MDR-TB is a manmade problem..it is costly, deadly, debilitating, and the biggest threat to our current TB control strategies 2 1 India has the highest TB burden in the world 3 4 2 5 M. tuberculosis Resistance
More informationQuality of Veterinary Medicinal Products. How to ensure the quality of Veterinary Medicinal Products
Quality of Veterinary Medicinal Products How to ensure the quality of Veterinary Medicinal Products Jean-Pierre Orand Anses/ANMV OIE Collaborating Centre on Veterinary medicinal products Jean-pierre.orand@anses.fr
More informationMedicine Price Monitor
Medicine Price Monitor Uganda Oct-Dec 2006 KEY FINDINGS: OVERALL 1. Medicines were more available in private sector health facilities than in public and mission sector facilities. 2. Prices of medicines
More informationAMR Industry Alliance Antibiotic Discharge Targets
AMR Industry Alliance Antibiotic Discharge Targets List of Predicted No-Effect Concentrations (PNECs) The members of the AMR Industry Alliance have developed a unified approach to establishing discharge
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 4: Antibiotic Resistance Author M.P. Stevens, MD, MPH S. Mehtar, MD R.P. Wenzel, MD, MSc Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationDEPARTMENT OF BIOLOGY ANTIMICROBIAL RESISTANCE IN THE DEVELOPING NATIONS OF BRICS STEPHANIE JEONG SPRING 2014
THE PENNSYLVANIA STATE UNIVERSITY SCHREYER HONORS COLLEGE DEPARTMENT OF BIOLOGY ANTIMICROBIAL RESISTANCE IN THE DEVELOPING NATIONS OF BRICS STEPHANIE JEONG SPRING 2014 A thesis submitted in partial fulfillment
More informationDevelopment and improvement of diagnostics to improve use of antibiotics and alternatives to antibiotics
Priority Topic B Diagnostics Development and improvement of diagnostics to improve use of antibiotics and alternatives to antibiotics The overarching goal of this priority topic is to stimulate the design,
More informationQuality of Veterinary Medicinal Products. How to ensure the quality of Veterinary Medicinal Products
Quality of Veterinary Medicinal Products How to ensure the quality of Veterinary Medicinal Products Gérard Moulin Anses/ANMV OIE Collaborating Centre on Veterinary medicinal products gerard.moulin@anses.fr
More informationOIE activities on rabies: PVS, vaccine banks and the OIE twinning
Dr Gardner Murray, Special Adviser World Organisation for Animal Health (OIE) OIE activities on rabies: PVS, vaccine banks and the OIE twinning OIE Global Conference on Rabies Control: with the support
More informationAmoxicillin Mg Dosage
Amoxicillin 875 125 Mg Dosage amoxicillin 500 mg dosage tooth infection buy amoxicillin online next day delivery amoxicillin 875 mg twice a day uses amoxicillin 500mg twice a day for sinus infection amoxicillin
More informationGARP ACTIVITIES IN KENYA. Sam Kariuki and Cara Winters
GARP ACTIVITIES IN KENYA Sam Kariuki and Cara Winters GARP-Kenya Situation Analysis Status of Conditions Related to Antibiotic Resistance 2010 Report Organization I. Health System Overview and Disease
More information